2018 Hepatic Insufficiency Drug Development- Pipeline Analysis Report

  • ID: 4527571
  • Report
  • 42 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • Avexegen Therapeutics
  • Glycosyn LLC
  • Leadiant Biosciences
  • ProMetic Life Sciences
  • MORE
Hepatic Insufficiency is a rare disease that can either present slow or rapid worsening of liver functioning. Young population is the most affected age group. The disease presents high mortality rates. Hepatitis infection, medication issues, alcohol are the primary reasons of the disease.

Over 30 companies and universities are focusing on developing treatment options for Liver Failure (Hepatic Insufficiency).

To assist investigators and funding and regulatory organizations, the publisher has come up with a comprehensive report on Liver Failure (Hepatic Insufficiency) pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Liver Failure (Hepatic Insufficiency) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Liver Failure (Hepatic Insufficiency) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Avexegen Therapeutics
  • Glycosyn LLC
  • Leadiant Biosciences
  • ProMetic Life Sciences
  • MORE
1.1 List of Figures
1.2 List of Tables

2 Hepatic Insufficiency Pipeline Analysis
2.1 Disease and Pipeline Overview
2.2 Hepatic Insufficiency Pipeline Snapshot
2.3 Hepatic Insufficiency Pipeline by Phase
2.4 Hepatic Insufficiency Pipeline by Company
2.5 Hepatic Insufficiency Pipeline by Mechanism of Action

3 Hepatic Insufficiency- Company Wise Pipeline Analysis
  • BioLineRx
  • Cell2B
  • HepaRegeniX GmbH
  • Martin Pharmaceuticals
  • Mina Therapeutics
  • Novartis AG
  • PledPharma AB
  • Promethera Biosciences
  • Proterris Inc
  • Steminent Biotherapeutics Inc
  • Therapure Biopharma
  • Unicyte AG
  • Versantis AG
  • Vital Therapies Inc
  • Xenexus Pharmaceuticals
4 Hepatic Insufficiency R&D Pipeline Snapshots
  • Drug wise Pipeline Details
  • Therapeutic Candidate Name
  • Originator
  • Co-Developer/ License Partner
  • Orphan Drug Designation
  • Development Phase
  • Mechanism of Action
  • Current Status
  • Ongoing Clinical Trial Details
5 Recent Developments in Hepatic Insufficiency Pipeline

6 Appendix
6.1 About the Publisher
6.2 Sources and Research Methodology

1.1 List of Figures
Figure 1: Hepatic Insufficiency Pipeline by Phase, H1- 2018
Figure 2: Hepatic Insufficiency Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Hepatic Insufficiency Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

1.2 List of Tables
Table 1: Hepatic Insufficiency Pipeline by Phase, H1- 2018
Table 2: Hepatic Insufficiency Pipeline by Companies, H1- 2018
Table 3: Hepatic Insufficiency Pipeline by Mechanism of Action, H1- 2018
Table 4: BioLineRx Hepatic Insufficiency pipeline, May 2018
Table 5: Cell2B Hepatic Insufficiency pipeline, May 2018
Table 6: HepaRegeniX GmbH Hepatic Insufficiency pipeline, May 2018
Table 7: Martin Pharmaceuticals Hepatic Insufficiency pipeline, May 2018
Table 8: Mina Therapeutics Hepatic Insufficiency pipeline, May 2018
Table 9: Novartis AG Hepatic Insufficiency pipeline, May 2018
Table 10: PledPharma AB Hepatic Insufficiency pipeline, May 2018
Table 11: Promethera Biosciences Hepatic Insufficiency pipeline, May 2018
Table 12: Proterris Inc Hepatic Insufficiency pipeline, May 2018
Table 13: Steminent Biotherapeutics Inc Hepatic Insufficiency pipeline, May 2018
Table 14: Therapure Biopharma Hepatic Insufficiency pipeline, May 2018
Table 15: Unicyte AG Hepatic Insufficiency pipeline, May 2018
Table 16: Versantis AG Hepatic Insufficiency pipeline, May 2018
Table 17: Vital Therapies Inc Hepatic Insufficiency pipeline, May 2018
Table 18: Xenexus Pharmaceuticals Hepatic Insufficiency pipeline, May 2018
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Avexegen Therapeutics
  • Glycosyn LLC
  • Infant Bacterial Therapeutics
  • Leadiant Biosciences
  • ProMetic Life Sciences
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll